Source desk / Skin products and injections
Compare GHK-Cu skin products and injections separately.
GHK-Cu pairs a short protein fragment with copper; skincare labels may call it copper tripeptide-1.
Before discussing results, ask what is being offered: something for the skin, or an injection.
The evidence comparison
What do studies in people tell us?
GHK-Cu had no FDA-approved medicine of any form as of 30 September 2026.
In this comparison, FDA means Food and Drug Administration.
| The question | Used on the skin | Given by injection |
|---|---|---|
| What has been tested in people? | Few studies have tested GHK-Cu in people, and most studied face creams, according to reviews checked in September 2026. | A search dated 30 September 2026 found no GHK-Cu injection study in ClinicalTrials.gov, a US public list of studies involving people. That finding concerns this list and search date; it does not rule out research elsewhere. |
| What remains uncertain? | The small skin studies available on 30 September 2026 cannot answer questions about rare side effects. | According to FDA’s warning, checked 30 September 2026, clumps or impurities in GHK-Cu injections might make the body’s defence system react. In the warning checked on 30 September 2026, FDA said it had too little evidence from people to judge injection safety. That warning does not tell us how such a reaction would look or feel in a person. Ask the prescriber what problems to watch for and who to call if you feel unwell. |
The status comparison
What do the FDA lists mean for a pharmacy offer?
With compounding, a pharmacist or doctor makes the preparation instead of using a finished medicine from a drug company.
If it is an injection
On FDA’s page dated 22 April 2026, “nominated but withdrawn” means the groups seeking permission to use GHK-Cu in compounded injections took back their requests.
Taking back that request did not approve the injection or give a pharmacy permission to make it (checked 30 September 2026).
If it is used without injections
Category 1 is FDA’s group for ingredients it is still assessing; its 14 May 2026 list includes GHK-Cu only for use without injections.
While it decides, FDA plans no action over using those ingredients if the pharmacy meets its guidance conditions (checked 30 September 2026).
As checked on 30 September 2026, that temporary policy did not approve GHK-Cu or declare that a pharmacy’s use of it was lawful.
This guide cannot confirm whether a particular pharmacy’s offer meets every legal requirement.
Ask the pharmacist to explain which rule allows this exact preparation, which conditions it meets, and how they checked them. Request a written answer.
The claim and its limits
Ask what was actually tested.
Ask the clinician to show the study behind the result being offered. Does it test this product, used this way, in people with the same goal?
There was no FDA-reviewed GHK-Cu label to explain effects with other medicines or use during pregnancy, as checked on 30 September 2026.
Bring a list of medicines, mention any pregnancy, and tell the prescriber about a diagnosed copper problem such as Wilson disease.
With Wilson disease, the body holds too much copper; the condition is inherited (source checked 30 September 2026).